SuperworthNephros EV/EBIT NEPH
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2023.
- Today, Oct 23, 2026
- 20.5×
- 3-year median
- 31.0×
- Against its 3-year history
- 11th
- percentile: 0 is its lowest day, 100 its highest
- 3-year range
- 15.8× to 63.4×
- Peer median
- 7.7×
Nephros' EV/EBIT is 20.5× as of Oct 23, 2026.
That is below its 3-year median of 31.0×, lower than on 89% of days in the last 3 years.
Over that time it ranged from 15.8× in Sep 2023 to 63.4× in Jun 2025.
The median for 6 medical instruments and supplies stocks of a similar size is 7.7×.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 20.5× | 20.5× | 61.6× |
| 2025 | 32.7× | 24.4× | 63.4× |
| 2024 | n/m a value too high to mean anything | ||
| 2023 | 19.2× | 15.8× | 51.7× |
Against its peers
Companies in Medical - Instruments & Supplies nearest Nephros' size, closest first, today.
| Company | EV/EBIT |
|---|---|
| NEPHNephros | 20.5× |
| APTAlpha Pro Tech | 8.2× |
| KEQUKewaunee Scientific | 7.2× |
| PDEXPro DEX | 16.0× |
| UTMDUtah Medical Products | 6.0× |
| INFUInfuSystem | 22.4× |
| EMBCEmbecta | 6.7× |
| Peer median | 7.7× |
Where Nephros ranks
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on Nephros
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.